MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses

With the clinical approval of T-cell–dependent immune checkpoint inhibitors for many cancers, therapeutic cancer vaccines have re-emerged as a promising immunotherapy. Cancer vaccines require the addition of immunostimulatory adjuvants to increase vaccine immunogenicity, and increasingly multiple ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, David, Meyer, Christian T., Graves, Diana, Sen, Rupashree, Fu, Juan, Tran, Emily, Mirza, Bilal, Rodriguez, Gabriel, Lang, Cara, Feng, Hanwen, Quaranta, Vito, Wilson, John T., Kim, Young J., Korrer, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437625/
https://www.ncbi.nlm.nih.gov/pubmed/36059502
http://dx.doi.org/10.3389/fimmu.2022.936129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437625/
https://www.ncbi.nlm.nih.gov/pubmed/36059502
http://dx.doi.org/10.3389/fimmu.2022.936129

Ejemplares similares